Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Dinan

Showing results (21-30 of 112) with videos related to

Pageof 12
Sort By:
JCO Precision Oncology|February 1, 2022
Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence GenerationMichaela A Dinan, Gary H Lyman, Richard L Schilsky, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 15, 2012
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancerShelby D Reed, Michaela A Dinan, Kevin A Schulman, et al.
Journal of the National Cancer Institute|September 17, 2024
Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer settingSydnie Stackland, Dominic Schnabel, Michaela A Dinan, et al.
Journal of Geriatric Oncology|November 30, 2020
Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015Lauren E Wilson, Melissa A Greiner, Ivy Altomare, et al.
Breast Cancer Research and Treatment|December 21, 2022
Genetic testing in privately insured women with surgically treated breast cancerMichaela A Dinan, Sarah Pitafi, Rachel A Greenup, et al.
American Journal of Hematology|December 24, 2009
Costs and length of stay for patients with and without sickle cell disease after hysterectomy, appendectomy, or knee replacementShital Kamble, Marilyn J Telen, Michaela A Dinan, et al.
JAMA Oncology|August 28, 2015
Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009Michaela A Dinan, Xiaojuan Mi, Shelby D Reed, et al.
Journal of Palliative Medicine|August 5, 2015
Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate CancerTimothy J Robinson, Michaela A Dinan, Yanhong Li, et al.
Archives of Internal Medicine|December 1, 1988
Fatal toxic epidermal necrolysis during prophylaxis with pyrimethamine and sulfadoxine in a human immunodeficiency virus-infected personM C Raviglione, W A Dinan, A Pablos-Mendez, et al.
Clinical Breast Cancer|July 13, 2020
Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial AdoptionMichaela A Dinan, Lauren E Wilson, Shelby D Reed, et al.
Pageof 12

Showing results (21-30 of 112) with videos related to

Sort By:
Pageof 12
JCO Precision Oncology|February 1, 2022
Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence GenerationMichaela A Dinan, Gary H Lyman, Richard L Schilsky, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 15, 2012
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancerShelby D Reed, Michaela A Dinan, Kevin A Schulman, et al.
Journal of the National Cancer Institute|September 17, 2024
Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer settingSydnie Stackland, Dominic Schnabel, Michaela A Dinan, et al.
Journal of Geriatric Oncology|November 30, 2020
Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015Lauren E Wilson, Melissa A Greiner, Ivy Altomare, et al.
Breast Cancer Research and Treatment|December 21, 2022
Genetic testing in privately insured women with surgically treated breast cancerMichaela A Dinan, Sarah Pitafi, Rachel A Greenup, et al.
American Journal of Hematology|December 24, 2009
Costs and length of stay for patients with and without sickle cell disease after hysterectomy, appendectomy, or knee replacementShital Kamble, Marilyn J Telen, Michaela A Dinan, et al.
JAMA Oncology|August 28, 2015
Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009Michaela A Dinan, Xiaojuan Mi, Shelby D Reed, et al.
Journal of Palliative Medicine|August 5, 2015
Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate CancerTimothy J Robinson, Michaela A Dinan, Yanhong Li, et al.
Archives of Internal Medicine|December 1, 1988
Fatal toxic epidermal necrolysis during prophylaxis with pyrimethamine and sulfadoxine in a human immunodeficiency virus-infected personM C Raviglione, W A Dinan, A Pablos-Mendez, et al.
Clinical Breast Cancer|July 13, 2020
Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial AdoptionMichaela A Dinan, Lauren E Wilson, Shelby D Reed, et al.
Pageof 12